Radioembolization in Elderly/ Fragile Patients With mCRC
NCT: NCT05092880 · TERMINATED
Brief Summary
Radioembolization (RE) is a minimally invasive treatment with administration of radioactive microspheres into the hepatic artery via a microcatheter. Since tumors are preferentially supplied by the hepatic artery, most microspheres get trapped in the tumor. RE has been shown a feasible and safe procedure for the treatment of unresectable CRC liver metastases. These data compare favourably with the toxicity data of capecitabine plus bevacizumab, but this should be validated in a prospective study. The proposed study investigates the efficacy of RE as an alternative, better tolerated and more cost-effective treatment option in elderly or frail patients compared to chronic systemic treatment with comparable progression-free survival.
Frequently Asked Questions
What is Radioembolization in Elderly/ Fragile Patients With mCRC?
Radioembolization in Elderly/ Fragile Patients With mCRC is a clinical trial registered under NCT05092880. Current status: TERMINATED.
What is the status of NCT05092880?
The current status of NCT05092880 (Radioembolization in Elderly/ Fragile Patients With mCRC) is: TERMINATED.
When did Radioembolization in Elderly/ Fragile Patients With mCRC start?
Radioembolization in Elderly/ Fragile Patients With mCRC started on 2022-06-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.